➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Express Scripts
Baxter
Colorcon

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Methylthioninium


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Methylthioninium?

Methylthioninium is an investigational drug.

There have been 5 clinical trials for Methylthioninium. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Adenocarcinoma, Dysuria, and Breast Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), I.M. Sechenov First Moscow State Medical University, and Prokhorov General Physics Institute of the Russian Academy of Sciences (GPI RAS).

There are thirty-two US patents protecting this investigational drug and seven hundred and eleven international patents.

Recent Clinical Trials for Methylthioninium
TitleSponsorPhase
COVID-19 Treatment Using Methylene Blue and Photodynamic TherapyProkhorov General Physics Institute of the Russian Academy of Sciences (GPI RAS)Phase 1
COVID-19 Treatment Using Methylene Blue and Photodynamic TherapyI.M. Sechenov First Moscow State Medical UniversityPhase 1
Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of DysuriaEMSPhase 3

See all Methylthioninium clinical trials

Clinical Trial Summary for Methylthioninium

Top disease conditions for Methylthioninium
Top clinical trial sponsors for Methylthioninium

See all Methylthioninium clinical trials

US Patents for Methylthioninium

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Methylthioninium ⤷  Try it Free Anti-Tau antibodies and methods of use Genentech, Inc. (South San Francisco, CA) AC Immune SA (Lausanne, CH) ⤷  Try it Free
Methylthioninium ⤷  Try it Free Humanized tau antibodies in a alzheimer's disease Axon Neuroscience SE (Larnaka, CY) ⤷  Try it Free
Methylthioninium ⤷  Try it Free Anti-Tau Antibodies and methods of use Genentech, Inc. (South San Francisco, CA) AC Immune SA (Lausanne, CH) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Baxter
Boehringer Ingelheim
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.